Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN 주식 보고서

시가총액: US$253.9m

Eledon Pharmaceuticals 관리

관리 기준 확인 2/4

Eledon Pharmaceuticals CEO는 DA Gros, Sep2020 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $ 2.55M, 21.9% 로 구성됩니다. 21.9% 급여 및 78.1% 보너스(회사 주식 및 옵션 포함). 는 $ 38.26K 가치에 해당하는 회사 주식의 0.015% 직접 소유합니다. 38.26K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 5.9 년입니다.

주요 정보

DA Gros

최고 경영자

US$2.6m

총 보상

CEO 급여 비율21.9%
CEO 임기4.2yrs
CEO 소유권0.02%
경영진 평균 재임 기간3.6yrs
이사회 평균 재임 기간5.9yrs

최근 관리 업데이트

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

CEO 보상 분석

DA Gros 의 보수는 Eledon Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$25m

Jun 30 2024n/an/a

-US$89m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$3mUS$559k

-US$117m

Sep 30 2023n/an/a

-US$145m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$1mUS$533k

-US$88m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$748kUS$504k

-US$35m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$7mUS$150k

-US$23m

보상 대 시장: DA 의 총 보상 ($USD 2.55M )은 US 시장( $USD 1.46M ).

보상과 수익: 회사가 수익성이 없는 동안 DA 의 보상이 증가했습니다.

CEO

DA Gros (52 yo)

4.2yrs

테뉴어

US$2,553,153

보상

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

리더십 팀

이름위치테뉴어보상소유권
David-Alexandre Gros
CEO & Non Independent Director4.2yrsUS$2.55m0.015%
$ 38.3k
Steven Perrin
President4.2yrsUS$1.54m0.0017%
$ 4.2k
Paul Little
Chief Financial Officer3.7yrsUS$1.32m0.017%
$ 42.5k
John Herberger
Vice President of Technical Operations2.5yrs데이터 없음데이터 없음
Bryan Smith
General Counsel3.6yrsUS$1.68m0%
$ 0
David Hovland
Chief Regulatory Officer3.6yrs데이터 없음데이터 없음
Eliezer Katz
Chief Medical Officer1.1yrs데이터 없음데이터 없음

3.6yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: ELDN 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
David-Alexandre Gros
CEO & Non Independent Director4.2yrsUS$2.55m0.015%
$ 38.3k
Steven Perrin
President4.2yrsUS$1.54m0.0017%
$ 4.2k
Keith Katkin
Independent Chairman of the Board7.5yrsUS$1.52m0.0011%
$ 2.9k
John McBride
Independent Director7.5yrsUS$371.82k0%
$ 0
James Robinson
Independent Director1.1yrsUS$201.79k데이터 없음
June Lee
Independent Director3.9yrsUS$374.44k0%
$ 0
Hamid Djalilian
Member of Scientific Advisory Board5.9yrs데이터 없음데이터 없음
Paola Marchisio
Member of Scientific Advisory Board5.9yrs데이터 없음데이터 없음
Tal Marom
Member of Scientific Advisory Board5.9yrs데이터 없음데이터 없음
Michael Pichichero
Member of Scientific Advisory Board5.9yrs데이터 없음데이터 없음
Anne Schilder
Member of Scientific Advisory Board5.9yrs데이터 없음데이터 없음
Seth Pranksy
Member of Scientific Advisory Board5.9yrs데이터 없음데이터 없음

5.9yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: ELDN 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.